Loading
companiesCompany
Merrimack Pharmaceuticals
Merrimack was the Cambridge biotech behind liposomal irinotecan (Onivyde), approved for pancreatic cancer in 2015 and later sold to Ipsen; its antibody programmes failed and the company wound down.
Also called: Merrimack Pharmaceuticals, Inc.Merrimack
Overview
Merrimack Pharmaceuticals, founded in 2000 in Cambridge, Massachusetts, developed MM-398, a liposomal formulation of irinotecan approved in 2015 as Onivyde for metastatic pancreatic cancer after gemcitabine (the NAPOLI-1 trial), which it sold to Ipsen in 2017. Its systems-biology antibody programmes, including the HER3 antibody seribantumab, did not reach approval, and the company later returned remaining assets to shareholders. Its phase 3 trials remain on ClinicalTrials.gov under Merrimack as lead sponsor.
Headquarters
Cambridge, MA, US
Scorecard
All companies#132of 1244 companies, score 44
- approved products +6
- modalities +2
- regions +6
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 1,640 registry studies. Formula on the scorecards page.
Type
Stage
Wound down
Website
Founded
2000
ApprovedTopoisomerase I inhibitor (camptothecin prodrug)
Irinotecan (and liposomal irinotecan) · Camptosar / Onivyde
Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads.
Similar pages
- CompanyLisata Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyPregLem
- CompanyAgennix
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyMedigene
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
cancers
drugs
ApprovedTopoisomerase I inhibitor (camptothecin prodrug)
Irinotecan (and liposomal irinotecan) · Camptosar / Onivyde